| Pharmaceutical Information |
| Drug Name |
Meprobamate |
| Drug ID |
BADD_D01390 |
| Description |
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S. |
| Indications and Usage |
For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. |
| Marketing Status |
approved; illicit |
| ATC Code |
N05BC01 |
| DrugBank ID |
DB00371
|
| KEGG ID |
D00376
|
| MeSH ID |
D008620
|
| PubChem ID |
4064
|
| TTD Drug ID |
D0Y4AW
|
| NDC Product Code |
62332-019; 46708-019; 69097-974; 66022-0105; 46708-020; 66064-4001; 51672-4148; 62332-020; 69097-975; 51672-4147 |
| UNII |
9I7LNY769Q
|
| Synonyms |
Meprobamate | Miltown | Méprobamate Richard | Meprospan | Tranmep | Visano | Equanil | Dapaz |
|
| Chemical Information |
| Molecular Formula |
C9H18N2O4 |
| CAS Registry Number |
57-53-4 |
| SMILES |
CCCC(C)(COC(=O)N)COC(=O)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
